RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Some fine questions, none of which I am going to try to answer here. There is an additional element that needs to be incorporated into the equation: the Organon compounds, 24448 and 26596. When you refer to the viability of chronic use, 24448 has more chronic use than any other Ampakine. But since Organon has said virtually nothing about completed studies, we don't know what that means, how many patients, for how long, how it turned out. Looking at the anticipated US studies, two were terminated, one is 'active, but not enrolling.' I have heard that Organon was going to reinitiate studies, but nothing has happened. That could be because of Schering-Plough, and a restriction on commitments.

I have heard nothing to suggest that the FDA put a hold on those studies, Stoll has said no artifact has been seen. But that's the big unknown--do those compounds provide any evidence of efficacy, and safety, in chronic use?

One other thought: In calculating the value of a program that uses a low-impact in acute use only, here is how I look at it:

How many crash carts are there in the United States? Each floor of each hospital, each wing of a nursing home, college infirmaries, drug detox centers, I'm sure I'm missing a slew of others. But that would be the market: Providing each crash cart with a RD 'solution' just in case. Maybe someone else would like to do some sleuthing--but I'm willing to bet that if you multiply that number by a suitable kit price--$300? $500? $1000? You'll get a sum that would look extremely good for a company like Cortex.

NeuroInvestment